Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Review By Dilip Davda on October 25, 2023
• MML is a 125 bed multi-speciality healthcare service provider.
• It marked declining trends in its top line from FY21 to FY23.
• The sudden boost in bottom line for FY23 despite lower top line surprises one and all.
• Based on its super FY24 annualized earnings, the issue appears fully priced.
• Well-informed investors may park funds for medium to long-term rewards.
PREFACE:
MML is a Surat based multi speciality hospital. Surprisingly, its offer document has financial data in Rupees Thousands, which appears to be an eyewash. Its high time for regulators to have common reporting system either in Rs. Lakhs or in Rs. Millions. The IPO price band ad also has mismatch on Market Maker reservation and post-IPO NAV based on the lower and upper cap.
(Note: The company gave corrigendum IPO price band ad with Market Maker portion clarification and post-IPO NAV data on October 27, 2023 on page no. 5 of Gujarat Guardian of Surat)
ABOUT COMPANY:
Maitreya Medicare Ltd. (MML) is a 125 bedded, Multi Superspeciality hospital incorporated in the year 2019 based out in Surat, Gujarat. It provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care. MML offers a comprehensive range of healthcare services across over 18 specialities and super specialities, including Cardiology, Urology, Oncology, Laparoscopic Surgery, Neurology, Neurosurgery, Spine Surgery, Nephrology including Dialysis, Gastroenterology, Gastrointestinal surgery, Cardiothoracic Surgery, Oncosurgery, Orthopedic Surgery including joint replacements and Arthroscopic surgeries, Gynecology & High-Risk Obstetrics, Hepatocellular Billary Surgery, Critical Care Medicine etc.
The company has grown from 67 bed capacity in 2021, to 100 beds capacity in 2022 and now 125 bed capacity in 2023. It is strategically focuses on the southern Gujarat healthcare market where the company has a strong understanding of regional nuances, customer culture and the mind set of medical professionals and where there is a growing need for quality and affordable healthcare services. The hospital also has integrated diagnostic services and pharmacies that cater to patients.
It follows a 'patient first' ideology by creating the good infrastructure with thrust on service delivery to all stake holders, be it patient, staff or doctors, technology and support to put patient-first and foremost and be futuristic and innovative in the delivery of healthcare services. As of the filing of the offer document, it had 375 employees on its payroll.
ISSUE DETAILS/CAPITAL HISTORY:
The company is coming out with its maiden book building route IPO of 1816000 equity shares of Rs. 10 each. It has announced a price band of Rs. 78 - Rs. 82 per share and mulls mobilizing Rs. 14.89 cr. at the upper cap. The issue opens for subscription on October 27, 2023, and will close on November 01, 2023. The minimum application to be made is for 1600 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 26.80% of the post-IPO paid-up capital of the company. From the net proceeds of the IPO funds, it will utilize Rs. 7.50 cr. for investment in the subsidiary - Maitreya Hospital, Rs. 1.00 cr. for redemption of preference shares, Rs. 5.00 cr. for working capital and the balance for general corporate purposes.
After reserving market maker portion, the company has allocated from the rest not more than 50% for QIBs, not less than 15% for HNIs and not less than 35% for Retail investors.
The issue is solely lead managed by GYR Capital Advisors Pvt. Ltd., and Link Intime India Pvt. Ltd. is the registrar of the issue. Giriraj Stock Broking Pvt. Ltd. is the market maker for the company.
Having issued initial equity shares at par, the company also issued bonus shares in the ratio of 495 for 1 in March 2023. The average cost of acquisition of shares y the promoters is Rs. 0.02, and Rs. 2.40 per share.
Post-IPO, MML's current paid-up capital of Rs. 4.96 cr. will stand enhanced to Rs. 6.78 cr. Based on the upper price band of the IPO, the company is looking for a market cap of Rs. 55.56 cr.
FINANCIAL PERFORMANCE:
On the financial performance front, for the last three fiscals, MML has posted total income/net profit of Rs. 57.04 cr. / Rs. 4.24 cr. (FY21), Rs. 49.74 cr. / Rs. 1.14 cr. (FY22), and Rs. 39.95 cr. / Rs. 4.23 cr. (FY23). For the H1 of FY24 ended on September 30, 2023, it earned a net profit of Rs. 2.54 cr. on a total income of Rs. 24.85 cr.
For the last three fiscals, MML has reported an average EPS of Rs. 5.88 and an average RoNW of 45.99%. The issue is priced at a P/BV of 3.64 based on its NAV of Rs. 22.55 as of September 30, 2023. IPO ad is missing data on post-IPO NAV based on its price band.
(As per the data published in Gujarat Guardian of October 27, 2023 on post-IPO NAV info, the issue is priced at a P/BV of 2.13 based on post-IPO NAV of Rs. 38.48 per share at the upper cap).
If we attribute annualized FY24 earnings to the post-IPO paid-up capital of the company, then the asking price is at a P/E of 10.92. Thus the issue appears fully priced.
For the reported periods, the company has posted PAT margins of 7.50% (FY21), 2.30% (FY22), 10.73% (FY23), and 10.25% (H1-FY24), and RoCE of 47.91%, 17.22%, 42.71% and 23.75% respectively for the reported periods.
DIVIDEND POLICY:
The company has not declared any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy based on its financial performance and future prospects.
COMPARISON WITH LISTED PEERS:
As per the offer document, the company has shown Shalby Ltd., KMC Speciality Hospital, Global Health as their listed peers. They are trading at a P/E of 30.39, 46.69, and 69.07 (as of October 25, 2023). However, they are not comparable on an apple-to-apple basis. This compare is nothing but an eyewash.
MERCHANT BANKER'S TRACK RECORD:
This is the 17th mandate from GYR Capital in the last three fiscals. Out of the last 10 listings, all opened at a premiums ranging from 3.79% to 179.38% on the day of listing.
Review By Dilip Davda on October 25, 2023
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.
About Dilip Davda
Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.
Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.
(Dilip Davda -SEBI registered Research Analyst-Mumbai,
Registration no. INH000003127 (Perpetual)
Email id: dilip_davda@rediffmail.com ).
The initial public offer (IPO) of Maitreya Medicare Limited offers an early investment opportunity in Maitreya Medicare Limited. A stock market investor can buy Maitreya Medicare Limited IPO shares by applying in IPO before Maitreya Medicare Limited shares get listed at the stock exchanges. An investor could invest in Maitreya Medicare Limited IPO for short term listing gain or a long term.
Read the Maitreya Medicare Limited IPO recommendations by the leading analyst and leading stock brokers.
Maitreya Medicare Limited IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Maitreya Medicare Limited IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.
Our recommendation for Maitreya Medicare Limited IPO is to subscribe for long term.
As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Maitreya Medicare Limited IPO.
The Maitreya Medicare Limited IPO allotment status will be available on or around November 6, 2023. The allotted shares will be credited in demat account by November 7, 2023. Visit Maitreya Medicare Limited IPO allotment status to check.
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
